GREY:IMVIF - Post by User
Comment by
qwerty22on Nov 30, 2020 3:17pm
168 Views
Post# 32002395
RE:RE:RE:IMV
RE:RE:RE:IMV If the KOLs from the presentation early this year are right then what matters is the long term disease stability and high tolerability of the drug in the responders. I guess a good PFS number will support that idea with a solid data point. If the company can signal that's the strength they move forward with, maximizing that feature of the drug in the next trial, then maybe the analysts see something new. If they can sketch out a plan going forward based on PFS/stability/QoL rather than just relying on the ORR number then maybe we get progress. I hope they have something solid to say on the regulatory front.
Breakthorough wrote: Actual ORR is 26%. There were four patients left. There was the chance that one of them reached PR, bringing 31% ORR. Even more importantly, the data of PFS ("Progression Free Survival") and OS ("Overall survival") will be almost complete. Almost, because F Ors said the trial was to finish in 1Q 2021 (good news as far as it means some patients are still continuing on treatment).